SCHEDULE: Anson Funds Discloses 2.9% Stake in Spero Therapeutics
Beneficial Ownership Disclosure
Anson Funds Management LP and its affiliates reported a passive 2.9% beneficial ownership stake in Spero Therapeutics, Inc. as of June 30, 2025.
Summary
- Anson Funds Management LP, along with Anson Management GP LLC, Tony Moore, Anson Advisors Inc., Amin Nathoo, and Moez Kassam, collectively reported beneficial ownership of 1,615,469 shares of Spero Therapeutics, Inc. common stock.
- This ownership represents 2.9% of Spero Therapeutics' outstanding common stock.
- The percentage is calculated based on 55,910,641 shares outstanding, as reported in Spero Therapeutics' Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: This is a neutral, factual disclosure of passive beneficial ownership and does not reflect on the company's performance or outlook.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Disclosure of a passive ownership stake by an institutional investor group.
Key Dates
| Date | Description |
|---|---|
| 2025-05-13 | Date of Issuer's Quarterly Report on Form 10-Q, which reported 55,910,641 shares outstanding. |
| 2025-06-30 | Date of event requiring the filing of this statement (reporting period end date). |
| 2025-08-14 | Date of filing of this Schedule 13G Amendment No. 2. |
Keywords
Spero Therapeutics, Anson Funds, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Biotechnology, Pharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.